IMMUNE-MEDIATED MYOCARDITIS FOLLOWING SINGLE DOSE OF ADJUVANT ATEZOLIZUMAB: DOES BENEFIT OUTWEIGH RISK?

Authors

Harjit Singh

Publication/Presentation Date

3-2023

Volume

81

Issue

8

First Page

2537

Last Page

2537

Published In/Presented At

https://doi.org/10.1016/S0735-1097(23)02981-9

Disciplines

Medicine and Health Sciences

Department(s)

Fellows and Residents

Document Type

Article